The following is a summary of “Feasibility of trancutaneous auricular vagus nerve stimulation in Black and Hispanic/Latino people with peripheral neuropathy,” published in the January 2025 issue of ...

Bicycle Therapeutics' BT8009 offers strong safety and efficacy. Find out why BCYC stock could be a buy, despite recent volatility and awaiting mid-2025 data.

The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...

There is an underdiagnosed condition called statin-induced autoimmune myopathy. It can take years to show up and can be hard ...

The phase 2 REST trial by Frida Bugge Askeland and colleagues, reported in The Lancet Haematology, provides insight into ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

Trusted resource of information on Medical Oncology that includes articles, news, diet & nutrition, multimedia presentations, ...

Among older adults with classical Hodgkin lymphoma, frontline N-AVD has been found to be highly effective and well-tolerated.

The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...